Ardelyx Shares Preliminary Data On Use Of IBSRELA In Pediatric IBS-C Patients At NASPGHAN 2023
Portfolio Pulse from Benzinga Newsdesk
Ardelyx, Inc. (NASDAQ:ARDX) has shared preliminary data on the use of IBSRELA (tenapanor) in pediatric patients at the 2023 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting. The data, while preliminary and blinded to treatment assignment, is an important step towards assessing the safety and efficacy of IBSRELA among pediatric populations. The company is currently conducting a Phase 3 trial to assess the safety, tolerability, and efficacy of tenapanor in patients ages 12 to 17 with IBS-C.
October 04, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ardelyx's preliminary data on the use of IBSRELA in pediatric patients could potentially open a new market segment for the company if the drug proves to be safe and effective in this age group. However, the data is still preliminary and the study is ongoing.
The news is directly related to Ardelyx and its product IBSRELA. The preliminary data could potentially open a new market segment for the company, which could have a positive impact on its stock. However, the data is still preliminary and the study is ongoing, which means there is still uncertainty about the final results and their potential impact.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100